8-K: Cardinal Health Issues $1 Billion in Notes for Solaris Health Acquisition

Cardinal Health, Inc. completed a public offering of $1 billion in new notes to partially fund its proposed acquisition of Solaris Health.

Summary

• Cardinal Health, Inc. issued $600 million of 4.500% Notes due 2030 and $400 million of 5.150% Notes due 2035, totaling $1 billion in aggregate principal amount.
• The net proceeds are intended to fund a portion of the proposed acquisition of Solaris Health and associated fees and expenses.
• Pending the acquisition, funds may be used for general corporate purposes.
• A special mandatory redemption at 101% of principal plus accrued interest will occur if the Solaris Health acquisition is not completed by August 12, 2026, or if the company decides not to proceed.
• The notes are subject to optional redemption by the Issuer and repurchase at the option of holders upon a Change of Control Repurchase Event.

Sentiment

Score: 7

Explanation: The filing details a successful debt offering to fund a strategic acquisition, which is generally positive for growth. However, it also introduces new debt and the inherent risks associated with the acquisition's consummation and potential redemption clauses, balancing the overall sentiment to moderately positive.

Positives

• Successful issuance of $1 billion in notes indicates market confidence in Cardinal Health's creditworthiness and strategic direction.
• Securing financing for the Solaris Health acquisition demonstrates progress towards strategic growth initiatives.
• The special mandatory redemption clause at 101% provides a degree of protection for noteholders if the acquisition fails.

Negatives

• Incurrence of additional debt increases the company's leverage.
• The acquisition of Solaris Health is a proposed transaction, and its failure would trigger a special mandatory redemption, potentially requiring the company to re-evaluate its capital structure.
• Proceeds from the notes are not held in escrow, meaning the company has immediate access and flexibility, but also carries the risk of using funds for general corporate purposes if the acquisition falls through.

Risks

• The proposed acquisition of Solaris Health may not be consummated on or before the later of August 12, 2026, or any extended date, or the company may decide not to pursue it, triggering a special mandatory redemption.
• A 'Change of Control Repurchase Event' (Change of Control combined with a Below Investment Grade Rating Event) could require the Issuer to repurchase notes at 101% of principal plus accrued interest, potentially straining liquidity.
• The company's ability to meet its debt obligations could be affected by future economic conditions or operational performance.
• Changes in interest rates could impact the cost of future financing or the attractiveness of the notes.

Future Outlook

The company intends to use the proceeds from the notes offering to fund a portion of its proposed acquisition of Solaris Health, indicating a strategic move towards expanding its business. The terms of the notes include provisions for a special mandatory redemption if the acquisition is not consummated by August 12, 2026, or if the company decides not to proceed, providing clarity on the financial implications of the acquisition's outcome.

Management Comments

• The Executive Committee of the Board of Directors of the Issuer, upon authority delegated by the Board of Directors of the Issuer, pursuant to resolutions duly adopted, has duly authorized the issuance by the Issuer of $600,000,000 aggregate principal amount of the 2030 Notes and $400,000,000 aggregate principal amount of the 2035 Notes.
• The Issuer has requested that the Trustee execute and deliver this Third Supplemental Indenture.

Industry Context

The issuance of long-term debt to finance an acquisition is a common strategy for established companies seeking to expand market share or diversify operations. The specific acquisition of Solaris Health suggests Cardinal Health is strengthening its position in the healthcare services or distribution sector, potentially in a specialized area like gastroenterology, given the mention of "The GI Alliance Holdings, LLC" (GIA) as a majority-owned subsidiary involved in the acquisition agreement. The interest rates of 4.500% and 5.150% reflect prevailing market conditions for corporate debt at the time of issuance for a company with Cardinal Health's credit profile.

Comparison to Industry Standards

• The interest rates of 4.500% for 5-year notes and 5.150% for 10-year notes are competitive for an investment-grade issuer in the healthcare distribution sector, reflecting current market interest rate environments and the company's credit standing.
• The 101% special mandatory redemption premium for a failed acquisition is a standard protective covenant for bondholders in acquisition-related financings, similar to terms seen in offerings by peers like McKesson Corporation or AmerisourceBergen Corporation when raising debt for strategic M&A.
• Covenants limiting liens and subsidiary indebtedness to 3.0% of Consolidated Total Assets are typical for unsecured debt offerings by large, diversified healthcare companies, providing flexibility while maintaining a degree of protection for bondholders against excessive leverage or asset encumbrance.

Corporate Governance

Stakeholder Impact

• Shareholders: The debt issuance provides capital for strategic growth (Solaris Health acquisition), which could lead to increased shareholder value if the acquisition is successful. However, increased debt also adds financial risk.
• Noteholders (Investors in 2030/2035 Notes): Receive fixed interest payments and have specific redemption and repurchase rights, including a 101% special mandatory redemption if the acquisition fails, offering a degree of downside protection.
• Employees: The acquisition of Solaris Health could lead to integration efforts, potentially impacting employees of both Cardinal Health and Solaris Health through new opportunities or restructuring.
• Customers/Suppliers: The acquisition could lead to changes in service offerings or supply chain dynamics, depending on the nature of Solaris Health's business and its integration with Cardinal Health.
• Creditors: The issuance of new debt increases Cardinal Health's overall leverage, which could affect its credit profile and the risk assessment for existing and future creditors.

Next Steps

• Consummation of the proposed acquisition of Solaris Health.
• Regular semi-annual interest payments on the 2030 Notes and 2035 Notes, commencing March 15, 2026.
• Potential special mandatory redemption of notes if the Solaris Health acquisition is not completed or pursued by August 12, 2026 (or extended date).
• Ongoing compliance with covenants related to limitations on liens, sale and lease-back transactions, and subsidiary indebtedness.

Key Dates

Recommendation

The issuance of $1 billion in notes to fund a strategic acquisition is a significant event, but it is a financing mechanism for a proposed transaction rather than a direct indicator of immediate operational performance. While the acquisition of Solaris Health could be a positive long-term growth driver, the inherent risks of M&A, coupled with the increased debt load, suggest a 'hold' recommendation. Investors should monitor the consummation of the acquisition and its integration, as well as the company's ongoing financial performance and leverage ratios, before making further investment decisions. The special mandatory redemption clause offers some protection for bondholders, but the impact on equity holders is more nuanced and depends on the successful execution of the acquisition and subsequent value creation.

Keywords

Cardinal Health, Debt Offering, Corporate Bonds, Notes Due 2030, Notes Due 2035, Solaris Health Acquisition, Fixed Income, SEC Filing, Capital Raise, Corporate Finance